Twist Bioscience and South Bow Rated Bullish as Analysts Initiate Coverage

Key Facts

As institutional interest intensifies across biotechnology and energy infrastructure sectors, new bullish signals have emerged for mid-cap growth stocks. Piper Sandler initiated coverage on Twist Bioscience with an 'Overweight' rating and an $85.00 price target, citing the company's leadership in synthetic biology and genomics. Simultaneously, Raymond James launched coverage of South Bow Corporation with an 'Outperform' rating and a C$60 price target, highlighting its strategic crude oil pipeline assets and potential expansion projects.

These initiations come as energy infrastructure firms gain momentum; TC Energy, from which South Bow recently spun off, reported solid quarterly results that bolster analyst optimism for the energy logistics sector according to recent earnings reports. In the synthetic biology space, the new rating positions TWST competitively against peers, with the price target reflecting a more optimistic outlook than the previous analyst consensus of approximately $58 per share per market data.

Investors should monitor current price levels, as TWST closed at $74.05 (close June 11, 2026), sitting roughly 13% below the Piper Sandler target. Looking ahead at the economic calendar, broader market sentiment may be influenced by upcoming US inflation data, while energy sector observers will be watching for updates on major pipeline projects that could impact South Bow's valuation in the coming weeks.